

CITATION REPORT

List of articles citing

Presence of multiple lesion types with vastly different microenvironments in C3HeB/FeJ mice following aerosol infection with *Mycobacterium tuberculosis*

DOI: 10.1242/dmm.019570

DMM Disease Models and Mechanisms, 2015, 8, 591-602.

Source: <https://exaly.com/paper-pdf/61276397/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
113	Heterogeneous disease progression and treatment response in a C3HeB/FeJ mouse model of tuberculosis. <i>DMM Disease Models and Mechanisms</i> , 2015 , 8, 603-10	4.1	74
112	Experimental Models of Foamy Macrophages and Approaches for Dissecting the Mechanisms of Lipid Accumulation and Consumption during Dormancy and Reactivation of Tuberculosis. 2016 , 6, 122		4 ²
111	Unravelling the Secrets of Mycobacterial Cidality through the Lens of Antisense. 2016 , 11, e0154513		5
110	Mouse model of pulmonary cavitary tuberculosis and expression of matrix metalloproteinase-9. <i>DMM Disease Models and Mechanisms</i> , 2016 , 9, 779-88	4.1	39
109	Spectinamides are effective partner agents for the treatment of tuberculosis in multiple mouse infection models. 2017 , 72, 770-777		19
108	Phenotypic Heterogeneity in Mycobacterium tuberculosis. 2016 , 4,		34
107	Sterilizing Activity of Pyrazinamide in Combination with First-Line Drugs in a C3HeB/FeJ Mouse Model of Tuberculosis. 2016 , 60, 1091-6		22
106	Bedaquiline and Pyrazinamide Treatment Responses Are Affected by Pulmonary Lesion Heterogeneity in Infected C3HeB/FeJ Mice. 2016 , 2, 251-267		73
105	Host-directed therapy targeting the Mycobacterium tuberculosis granuloma: a review. 2016 , 38, 167-83		71
104	Mouse models of human TB pathology: roles in the analysis of necrosis and the development of host-directed therapies. 2016 , 38, 221-37		84
103	Pathology and immune reactivity: understanding multidimensionality in pulmonary tuberculosis. 2016 , 38, 153-66		87
102	Nitric oxide prevents a pathogen-permissive granulocytic inflammation during tuberculosis. 2017 , 2, 17072		146
101	Pathology of Tuberculosis: How the Pathology of Human Tuberculosis Informs and Directs Animal Models. 2017 , 5,		21
100	Addressing the Metabolic Stability of Antituberculars through Machine Learning. 2017 , 8, 1099-1104		11
99	NOS2-deficient mice with hypoxic necrotizing lung lesions predict outcomes of tuberculosis chemotherapy in humans. 2017 , 7, 8853		15
98	Preclinical Efficacy Testing of New Drug Candidates. 2017 , 5,		25
97	"Genetic regulation of Mycobacterium tuberculosis in a lipid-rich environment". 2017 , 55, 392-402		8

96	The C3HeB/FeJ mouse model recapitulates the hallmark of bovine tuberculosis lung lesions following Mycobacterium bovis aerogenous infection. 2017 , 48, 73	8
95	Preclinical Efficacy Testing of New Drug Candidates. 2017 , 269-293	0
94	Phenotypic Heterogeneity in Mycobacterium tuberculosis. 2017 , 671-697	1
93	Pathology of Tuberculosis: How the Pathology of Human Tuberculosis Informs and Directs Animal Models. 2017 , 117-129	1
92	Horizontal acquisition of a hypoxia-responsive molybdenum cofactor biosynthesis pathway contributed to Mycobacterium tuberculosis pathoadaptation. 2017 , 13, e1006752	18
91	Fluorescent Mycobacterium tuberculosis reporters: illuminating host-pathogen interactions. 2018 , 76,	21
90	Visualization of Mycobacterial Biomarkers and Tuberculosis Drugs in Infected Tissue by MALDI-MS Imaging. 2018 , 90, 6275-6282	35
89	Host-directed therapies for bacterial and viral infections. 2018 , 17, 35-56	280
88	Beyond Killing : Disease Tolerance. 2018 , 9, 2976	17
87	Human Monocytic Suppressive Cells Promote Replication of and Alter Stability of Generated Granulomas. 2018 , 9, 2417	19
86	Tuberculosis Histopathology on X Ray CT. 2018 , 169-179	2
85	Impact of immunopathology on the antituberculous activity of pyrazinamide. 2018 , 215, 1975-1986	19
84	Delineating the Physiological Roles of the PE and Catalytic Domains of LipY in Lipid Consumption in Mycobacterium-Infected Foamy Macrophages. 2018 , 86,	21
83	Influence of Gut Microbiota on Progression to Tuberculosis Generated by High Fat Diet-Induced Obesity in C3HeB/FeJ Mice. 2019 , 10, 2464	17
82	Matrix metalloproteinases: Expression, regulation and role in the immunopathology of tuberculosis. 2019 , 52, e12649	31
81	Synergistic Efficacy of β -Lactam Combinations against Pulmonary Infection in Mice. 2019 , 63,	19
80	Contribution of Pretomanid to Novel Regimens Containing Bedaquiline with either Linezolid or Moxifloxacin and Pyrazinamide in Murine Models of Tuberculosis. 2019 , 63,	32
79	Transmission phenotype of Mycobacterium tuberculosis strains is mechanistically linked to induction of distinct pulmonary pathology. 2019 , 15, e1007613	16

78	Treatment-Shortening Effect of a Novel Regimen Combining Clofazimine and High-Dose Rifapentine in Pathologically Distinct Mouse Models of Tuberculosis. 2019 , 63,	11
77	Humanized Mouse Model Mimicking Pathology of Human Tuberculosis for Evaluation of Drug Regimens. 2019 , 10, 89	8
76	Efficacy and Improved Resistance Potential of a Cofactor-Independent InhA Inhibitor of Mycobacterium tuberculosis in the C3HeB/FeJ Mouse Model. 2019 , 63,	6
75	X-ray-based virtual slicing of TB-infected lungs. 2019 , 9, 19404	2
74	Preserved Efficacy and Reduced Toxicity with Intermittent Linezolid Dosing in Combination with Bedaquiline and Pretomanid in a Murine Tuberculosis Model. 2020 , 64,	10
73	BCG-Prime and boost with Esx-5 secretion system deletion mutant leads to better protection against clinical strains of Mycobacterium tuberculosis. 2020 , 38, 7156-7165	2
72	Platelets Restrict the Oxidative Burst in Phagocytes and Facilitate Primary Progressive Tuberculosis. 2020 , 202, 730-744	3
71	OPC-167832, a Novel Carbostyryl Derivative with Potent Antituberculosis Activity as a DprE1 Inhibitor. 2020 , 64,	27
70	A radiological score for the assessment of tuberculosis progression: Validation in mouse models. 2020 , 121, 101918	0
69	Mouse transcriptome reveals potential signatures of protection and pathogenesis in human tuberculosis. 2020 , 21, 464-476	28
68	Caseum: a Niche for Mycobacterium tuberculosis Drug-Tolerant Persisters. 2020 , 33,	17
67	A mouse model of pulmonary Mycobacteroides abscessus infection. 2020 , 10, 3690	21
66	Digital Image Analysis of Heterogeneous Tuberculosis Pulmonary Pathology in Non-Clinical Animal Models using Deep Convolutional Neural Networks. 2020 , 10, 6047	6
65	The Bewildering Antitubercular Action of Pyrazinamide. 2020 , 84,	15
64	Targeting immunometabolism in host defence against Mycobacterium tuberculosis. 2021 , 162, 145-159	12
63	Advances in Host-Directed Therapies Against Tuberculosis. 2021 ,	2
62	Development of New Tuberculosis Drugs: Translation to Regimen Composition for Drug-Sensitive and Multidrug-Resistant Tuberculosis. 2021 , 61, 495-516	9
61	Perspectives and Advances in the Understanding of Tuberculosis. 2021 , 16, 377-408	5

60	Tailored co-localization analysis of intracellular microbes and punctum-distributed phagosome-lysosome pathway proteins using ImageJ plugin EzColocalization. 2021 , 11, 1096	1
59	Systematic measurement of combination drug landscapes to predict in vivo treatment outcomes for tuberculosis.	1
58	Lactate Metabolism and Signaling in Tuberculosis and Cancer: A Comparative Review. 2021 , 11, 624607	8
57	One Size Fits All? Not in Modeling of Tuberculosis Chemotherapeutics. 2021 , 11, 613149	2
56	Biofilm formation in the lung contributes to virulence and drug tolerance of Mycobacterium tuberculosis. 2021 , 12, 1606	23
55	Antitubercular Agents. 1-110	
54	Mycobacterium tuberculosis precursor rRNA as a measure of treatment-shortening activity of drugs and regimens. 2021 , 12, 2899	10
53	Inhibition of granuloma triglyceride synthesis imparts control of Mycobacterium tuberculosis through curtailed inflammatory responses.	
52	Targeting Mycobacterium tuberculosis response to environmental cues for the development of effective antitubercular drugs. 2021 , 19, e3001355	2
51	Comparative Analysis of Pharmacodynamics in the C3HeB/FeJ Mouse Tuberculosis Model for DprE1 Inhibitors TBA-7371, PBTZ169, and OPC-167832. 2021 , 65, e0058321	4
50	Nos2 ^{-/-} mice infected with M. tuberculosis develop neurobehavioral changes and immunopathology mimicking human central nervous system tuberculosis.	
49	Systematic measurement of combination-drug landscapes to predict in vivo treatment outcomes for tuberculosis. 2021 , 12, 1046-1063.e7	4
48	Preclinical Evaluation of Inhalational Spectinamide-1599 Therapy against Tuberculosis. 2021 , 7, 2850-2863	0
47	Inhibition of Granuloma Triglyceride Synthesis Imparts Control of Through Curtailed Inflammatory Responses. 2021 , 12, 722735	1
46	Rapamycin modulates pulmonary pathology in a murine model of Mycobacterium tuberculosis infection. <i>DMM Disease Models and Mechanisms</i> , 2021 , 14,	4.1 0
45	Pharmacodynamic Correlates of Linezolid Activity and Toxicity in Murine Models of Tuberculosis. 2021 , 223, 1855-1864	7
44	Correlative Light Electron Ion Microscopy reveal in vivo localisation of bedaquiline in Mycobacterium tuberculosis infected lungs.	1
43	Progressive Mycobacterium abscessus lung infection in C3HeB/FeJ mice associated with corticosteroid administration.	1

42	Modeling and Simulation of Pretomanid Pharmacodynamics in Pulmonary Tuberculosis Patients. 2019,	3
41	Correlative light electron ion microscopy reveals in vivo localisation of bedaquiline in Mycobacterium tuberculosis-infected lungs. 2020, 18, e3000879	5
40	Hypervirulent Mycobacterium tuberculosis strain triggers necrotic lung pathology associated with enhanced recruitment of neutrophils in resistant C57BL/6 mice. 2017, 12, e0173715	21
39	Protective efficacy of an attenuated Mtb Δ prG vaccine in mice. 2020, 16, e1009096	7
38	Cording Bacilli Have a Key Role in the Progression towards Active Tuberculosis, Which is Stopped by Previous Immune Response. 2020, 8,	4
37	Animal models of tuberculosis: Lesson learnt. 2018, 147, 456-463	28
36	Intracellular growth of after macrophage cell death leads to serial killing of host cells. 2017, 6,	51
35	MicroRNA AND TUBERCULOSIS. 2018, 8, 309-315	1
34	Contribution of pretomanid to novel regimens containing bedaquiline with either linezolid or moxifloxacin and pyrazinamide in murine models of tuberculosis.	
33	Treatment-shortening effect of a novel regimen combining high-dose rifapentine and clofazimine in pathologically distinct mouse models of tuberculosis.	
32	Preserved efficacy and reduced toxicity with intermittent linezolid dosing in combination with bedaquiline and pretomanid in a murine TB model.	
31	C3HeB/FeJ as a Key Mouse Strain for Testing Host-Directed Therapies Against Tuberculosis. 2021, 267-273	o
30	Spatial relationships of intra-lesion heterogeneity in Mycobacterium tuberculosis microenvironment, replication status, and drug efficacy.	
29	Nos2 mice infected with M. tuberculosis develop neurobehavioral changes and immunopathology mimicking human central nervous system tuberculosis.. 2022, 19, 21	o
28	GSK2556286 is a novel antitubercular drug candidate effective in vivo with the potential to shorten tuberculosis treatment.	
27	Novel Regimens of Bedaquiline-Pyrazinamide Combined with Moxifloxacin, Rifabutin, Delamanid and/or OPC-167832 in Murine Tuberculosis Models.. 2022, e0239821	1
26	α -Interactions Stabilize PeptoMicelle-Based Formulations of Pretomanid Derivatives Leading to Promising Therapy Against Tuberculosis in Zebrafish and Mouse Models.	o
25	Spatial relationships of intra-lesion heterogeneity in Mycobacterium tuberculosis microenvironment, replication status, and drug efficacy.. 2022, 18, e1010459	o

- 24 Novel regimens of bedaquiline-pyrazinamide combined with moxifloxacin, rifabutin, delamanid and/or OPC-167832 in murine tuberculosis models.
- 23 Interleukin-13 overexpressing mice represent an advanced pre-clinical model for detecting the distribution of anti-mycobacterial drugs within centrally necrotizing granulomas. **2021**, AAC0158821 1
- 22 Data_Sheet_1.docx. **2018**,
- 21 Data_Sheet_1.docx. **2019**,
- 20 Data_Sheet_1.docx. **2019**,
- 19 GSK2556286 Is a Novel Antitubercular Drug Candidate Effective In Vivo with the Potential To Shorten Tuberculosis Treatment. 0
- 18 Tuberculosis Drug Discovery: Challenges and New Horizons. 4
- 17 Neutrophils reprograms the bone marrow to impair T-cell immunity during tuberculosis.
- 16 CWHM-12, an Antagonist of Integrin-Mediated Transforming Growth Factor-Beta Activation Confers Protection During Early Mycobacterium tuberculosis Infection in Mice. **2022**, 42, 421-429
- 15 Spatial multiomic profiling reveals the novel polarization of foamy macrophages within necrotic granulomatous lesions developed in lungs of C3HeB/FeJ mice infected with Mycobacterium tuberculosis. 12, 0
- 14 Intercellular communication and social behaviors in mycobacteria. 13, 0
- 13 Phenotypic adaptation of Mycobacterium tuberculosis to host-associated stressors that induce persister formation. 12, 1
- 12 Clofazimine as a comparator for preclinical efficacy evaluations of experimental therapeutics against pulmonary M. abscessus infection in mice. **2022**, 102268 0
- 11 Ohmyungamycin Promotes M1-like Inflammatory Responses to Enhance Host Defense against Mycobacteroides abscessus Infections. 0
- 10 Distinct contributions of the innate immune receptors TLR2 and RP105 to formation and architecture of structured lung granulomas in mice infected with Mycobacterium tuberculosis. 0
- 9 Uptake-independent killing of macrophages by extracellular aggregates of Mycobacterium tuberculosis ESX-1 and PDIM-dependent. 0
- 8 Efficacy of Replacing Linezolid with OTB-658 in Anti-Tuberculosis Regimens in Murine Models. 0
- 7 Mouse Models for Mycobacterium tuberculosis Pathogenesis: Show and Do Not Tell. **2023**, 12, 49 0

- 6 Interactions stabilize PeptoMicelle-based formulations of Pretomanid derivatives leading to promising therapy against tuberculosis in zebrafish and mouse models. **2023**, 354, 851-868
- 5 A Novel Tool to Identify Bactericidal Compounds against Vulnerable Targets in Drug-Tolerant M. tuberculosis found in Caseum.
- 4 Lung microenvironments harbor Mycobacterium tuberculosis phenotypes with distinct treatment responses.
- 3 Intranasal multivalent adenoviral-vectored vaccine protects against replicating and dormant M.tb in conventional and humanized mice. **2023**, 8,
- 2 The clinical-stage drug BTZ-043 accumulates in tuberculosis lesions and efficiently acts against Mycobacterium tuberculosis.
- 1 Uptake-independent killing of macrophages by extracellular Mycobacterium tuberculosis aggregates.